News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
702,271 Results
Type
Article (40579)
Company Profile (268)
Press Release (661424)
Section
Business (205732)
Career Advice (2368)
Deals (35681)
Drug Delivery (93)
Drug Development (81668)
Employer Resources (172)
FDA (16303)
Job Trends (14932)
News (348165)
Policy (32941)
Tag
2024 BioCapital Digital (7)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (5)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2604)
Accelerated approval (2)
Adcomms (20)
Allergies (80)
Alliances (49861)
ALS (76)
Alzheimer's disease (1339)
Antibody-drug conjugate (ADC) (99)
Approvals (16286)
Artificial intelligence (216)
Autoimmune disease (10)
Automation (14)
Bankruptcy (358)
Best Places to Work (11708)
BIOSECURE Act (18)
Biosimilars (95)
Biotechnology (187)
Bladder cancer (50)
Brain cancer (24)
Breast cancer (238)
Cancer (1827)
Cardiovascular disease (137)
Career advice (1941)
Career pathing (28)
CAR-T (133)
Cell therapy (379)
Cervical cancer (13)
Clinical research (65977)
Collaboration (714)
Compensation (415)
Complete response letters (18)
COVID-19 (2601)
CRISPR (33)
C-suite (186)
Cystic fibrosis (97)
Data (1772)
Decentralized trials (2)
Denatured (14)
Depression (37)
Diabetes (227)
Diagnostics (6406)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (106)
Drug pricing (94)
Drug shortages (25)
Duchenne muscular dystrophy (70)
Earnings (86232)
Editorial (30)
Employer branding (21)
Employer resources (148)
Events (112651)
Executive appointments (602)
FDA (17299)
Featured Employer (51)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (637)
Gene editing (91)
Generative AI (20)
Gene therapy (266)
GLP-1 (670)
Government (4503)
Grass and pollen (4)
Guidances (46)
Healthcare (19082)
Huntington's disease (22)
IgA nephropathy (20)
Immunology and inflammation (93)
Indications (24)
Infectious disease (2724)
Inflammatory bowel disease (129)
Inflation Reduction Act (8)
Influenza (44)
Intellectual property (72)
Interviews (399)
IPO (16615)
IRA (40)
Job creations (3660)
Job search strategy (1667)
Kidney cancer (9)
Labor market (29)
Layoffs (443)
Leadership (14)
Legal (7975)
Liver cancer (70)
Lung cancer (266)
Lymphoma (123)
Machine learning (2)
Management (59)
Manufacturing (250)
MASH (58)
Medical device (13464)
Medtech (13469)
Mergers & acquisitions (19493)
Metabolic disorders (591)
Multiple sclerosis (60)
NASH (17)
Neurodegenerative disease (70)
Neuropsychiatric disorders (23)
Neuroscience (1779)
NextGen: Class of 2025 (6614)
Non-profit (4525)
Northern California (2251)
Now hiring (36)
Obesity (324)
Opinion (198)
Ovarian cancer (61)
Pain (72)
Pancreatic cancer (70)
Parkinson's disease (122)
Partnered (17)
Patents (185)
Patient recruitment (84)
Peanut (46)
People (57493)
Pharmaceutical (66)
Pharmacy benefit managers (18)
Phase I (20552)
Phase II (29079)
Phase III (21611)
Pipeline (829)
Podcasts (40)
Policy (102)
Postmarket research (2585)
Preclinical (8695)
Press Release (64)
Prostate cancer (86)
Psychedelics (30)
Radiopharmaceuticals (243)
Rare diseases (343)
Real estate (5948)
Recruiting (65)
Regulatory (22282)
Reports (43)
Research institute (2358)
Resumes & cover letters (408)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (61)
Series A (115)
Series B (69)
Service/supplier (13)
Sickle cell disease (49)
Southern California (1937)
Special edition (15)
Sponsored (29)
Startups (3612)
State (2)
Stomach cancer (12)
Supply chain (57)
The Weekly (25)
United States (19864)
Vaccines (637)
Venture capitalists (35)
Webinars (12)
Weight loss (220)
Women's health (30)
Worklife (14)
Date
Today (82)
Last 7 days (613)
Last 30 days (2885)
Last 365 days (34305)
2025 (6196)
2024 (35496)
2023 (40436)
2022 (51587)
2021 (56153)
2020 (54533)
2019 (47171)
2018 (35494)
2017 (32562)
2016 (31900)
2015 (38005)
2014 (31704)
2013 (26756)
2012 (29001)
2011 (29766)
2010 (27698)
Location
Africa (764)
Alabama (48)
Alaska (7)
Arizona (215)
Arkansas (12)
Asia (38140)
Australia (6340)
California (5149)
Canada (1787)
China (421)
Colorado (235)
Connecticut (247)
Delaware (115)
Europe (83649)
Florida (764)
Georgia (177)
Idaho (57)
Illinois (473)
India (22)
Indiana (280)
Iowa (7)
Japan (129)
Kansas (99)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (792)
Massachusetts (3913)
Michigan (206)
Minnesota (351)
Mississippi (2)
Missouri (72)
Montana (27)
Nebraska (25)
Nevada (54)
New Hampshire (61)
New Jersey (1464)
New Mexico (27)
New York (1480)
North Carolina (884)
North Dakota (8)
Northern California (2251)
Ohio (181)
Oklahoma (13)
Oregon (32)
Pennsylvania (1167)
Puerto Rico (6)
Rhode Island (24)
South America (1142)
South Carolina (15)
South Dakota (1)
Southern California (1937)
Tennessee (85)
Texas (757)
Utah (157)
Virginia (123)
Washington D.C. (57)
Washington State (499)
West Virginia (3)
Wisconsin (44)
702,271 Results for "gel e inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
March 3, 2025
·
9 min read
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
May 29, 2024
·
3 min read
Press Releases
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
February 14, 2025
·
10 min read
Press Releases
PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson’s Disease
February 6, 2025
·
6 min read
Press Releases
Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects
February 4, 2025
·
6 min read
Press Releases
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
February 10, 2025
·
7 min read
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to Progena
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”) to ProgenaCare Global LLC (“ProgenaCare”).
June 27, 2024
·
4 min read
Press Releases
Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC
February 4, 2025
·
4 min read
Biotech Bay
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
XOMA Corporation announced it has acquired an economic interest in three women’s health assets - XACIATO™ vaginal gel 2%, Ovaprene®, and Sildenafil Cream, 3.6% - from Daré Bioscience, Inc., for an upfront payment of $22 million.
April 30, 2024
·
7 min read
FDA
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
October 7, 2024
·
5 min read
1 of 70,228
Next
